Key Points
- Director William Mr. Burke sold 19,227 shares on November 10 at an average of $24.01 for a total of $461,640, leaving him with 100 shares — a 99.48% drop in his ownership.
- AxoGen beat recent quarterly estimates (EPS $0.12 vs $0.09; revenue $60.08M vs $56.90M) but still shows negative net margin and ROE, while analysts have raised price targets and the consensus target sits at about $28.86 with mostly Buy ratings.
AxoGen, Inc. (NASDAQ:AXGN - Get Free Report) Director William Mr. Burke sold 3,591 shares of the business's stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $24.02, for a total value of $86,255.82. Following the sale, the director owned 100 shares in the company, valued at $2,402. The trade was a 97.29% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
AxoGen Stock Performance
AxoGen stock traded down $0.56 during midday trading on Friday, hitting $23.48. 181,379 shares of the company were exchanged, compared to its average volume of 838,361. The business has a fifty day simple moving average of $18.56 and a two-hundred day simple moving average of $14.73. The company has a debt-to-equity ratio of 0.59, a quick ratio of 2.67 and a current ratio of 4.14. The firm has a market capitalization of $1.08 billion, a PE ratio of -470.10 and a beta of 1.09. AxoGen, Inc. has a fifty-two week low of $9.22 and a fifty-two week high of $24.92.
AxoGen (NASDAQ:AXGN - Get Free Report) last announced its earnings results on Wednesday, October 29th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.03. AxoGen had a negative net margin of 0.98% and a negative return on equity of 1.96%. The business had revenue of $60.08 million for the quarter, compared to analyst estimates of $56.90 million. AxoGen has set its FY 2025 guidance at EPS. On average, sell-side analysts forecast that AxoGen, Inc. will post -0.29 earnings per share for the current year.
Analyst Ratings Changes
Several brokerages have weighed in on AXGN. Weiss Ratings restated a "sell (e+)" rating on shares of AxoGen in a report on Thursday. Citizens Jmp raised their target price on shares of AxoGen from $26.00 to $34.00 and gave the company a "market outperform" rating in a report on Thursday, October 30th. JMP Securities set a $34.00 price target on shares of AxoGen in a report on Thursday, October 30th. Wall Street Zen raised shares of AxoGen from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Finally, Raymond James Financial raised their price target on AxoGen from $20.00 to $27.00 and gave the company an "outperform" rating in a research note on Thursday, October 30th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $28.86.
Get Our Latest Stock Report on AxoGen
Institutional Trading of AxoGen
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Balyasny Asset Management L.P. grew its holdings in AxoGen by 183.9% in the second quarter. Balyasny Asset Management L.P. now owns 1,931,158 shares of the medical equipment provider's stock valued at $20,953,000 after purchasing an additional 1,250,968 shares during the period. Bessemer Group Inc. purchased a new position in shares of AxoGen in the 3rd quarter worth $14,468,000. Wasatch Advisors LP boosted its holdings in AxoGen by 85.1% in the second quarter. Wasatch Advisors LP now owns 1,433,782 shares of the medical equipment provider's stock valued at $15,557,000 after acquiring an additional 659,149 shares during the last quarter. Brown Capital Management LLC purchased a new stake in AxoGen during the third quarter valued at about $11,500,000. Finally, Armistice Capital LLC increased its stake in AxoGen by 106.5% during the second quarter. Armistice Capital LLC now owns 1,111,319 shares of the medical equipment provider's stock worth $12,058,000 after acquiring an additional 573,041 shares during the last quarter. Hedge funds and other institutional investors own 80.29% of the company's stock.
AxoGen Company Profile
(
Get Free Report)
AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
